Nuvaira Secures $79 Million to Study Minimally Invasive COPD Treatment
Nuvaira, a medical device company, announced it has secured $79 million to support the AIRFLOW-3 clinical trial to assess the company’s new targeted lung denervation (TLD) system, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). COPD includes a group of diseases characterized by chronic airway obstruction…